Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Final OS results of IMvigor130: Atezolizumab plus platinum/gemcitabine for mUC

Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA
Final OS results of IMvigor130: Atezolizumab plus platinum/gemcitabine for mUC ( Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA )
18 Feb 2023

Nivolumab and salvage nivolumab plus ipilimumab for aRCC

Prof Michael Atkins - Georgetown Lombardi Comprehensive Cancer Center, Georgetown, USA
Nivolumab and salvage nivolumab plus ipilimumab for aRCC ( Prof Michael Atkins - Georgetown Lombardi Comprehensive Cancer Center, Georgetown, USA )
18 Feb 2023

Gemcitabine, cisplatin plus nivolumab achieves clinical complete response in subset of muscle-invasive bladder cancer patients

Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA
Gemcitabine, cisplatin plus nivolumab achieves clinical complete response in subset of muscle-invasive bladder cancer patients ( Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA )
18 Feb 2023

Adjuvant nivolumab as standard of care for high-risk muscle-invasive urothelial carcinoma after radical resection

Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA
Adjuvant nivolumab as standard of care for high-risk muscle-invasive urothelial carcinoma after radical resection ( Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA )
18 Feb 2023

Anti-PSMA antibody radiolabeled with 177Lu improves MFS in high-risk nmCRPC

Prof Scott Tagawa - Weill Cornell Medicine, New York City, USA
Anti-PSMA antibody radiolabeled with 177Lu improves MFS in high-risk nmCRPC ( Prof Scott Tagawa - Weill Cornell Medicine, New York City, USA )
18 Feb 2023

Erdafitinib demonstrates efficacy in intermediate-risk non–muscle-invasive bladder cancer with FGFR alterations

Prof Siamak Daneshmand - University of Southern California, Los Angeles, USA
Erdafitinib demonstrates efficacy in intermediate-risk non–muscle-invasive bladder cancer with FGFR alterations ( Prof Siamak Daneshmand - University of Southern California, Los Angeles, USA )
18 Feb 2023

Cell-free utDNA may predict transurethral resection of bladder tumour pathology in non–muscle invasive bladder cancer

Dr Kyle Rose - Moffitt Cancer Center, Florida, USA
Cell-free utDNA may predict transurethral resection of bladder tumour pathology in non–muscle invasive bladder cancer ( Dr Kyle Rose - Moffitt Cancer Center, Florida, USA )
18 Feb 2023

IMvigor130 study: Final OS analysis of atezo + plt/gem vs placebo + plt/gem used to treat mUC

Prof Aristotelis Bamias - University of Athens, Athens, Greece
IMvigor130 study: Final OS analysis of atezo + plt/gem vs placebo + plt/gem used to treat mUC ( Prof Aristotelis Bamias - University of Athens, Athens, Greece )
18 Feb 2023

Hypofractionated high dose intensity modulated radiotherapy non-inferior for prostate cancer

Prof Joe M O'Sullivan - Queen's University Belfast, Belfast, UK
Hypofractionated high dose intensity modulated radiotherapy non-inferior for prostate cancer ( Prof Joe M O'Sullivan - Queen's University Belfast, Belfast, UK )
17 Feb 2023

JAVELIN Bladder 100: Avelumab maintenance indicated as a standard of care for advanced urothelial carcinoma

Dr Srikala Sridhar - Princess Margaret Cancer Centre, Ontario, Canada
JAVELIN Bladder 100: Avelumab maintenance indicated as a standard of care for advanced urothelial carcinoma ( Dr Srikala Sridhar - Princess Margaret Cancer Centre, Ontario, Canada )
16 Feb 2023

Stereotactic body radiotherapy compared with surgery for localised prostate cancer

Dr Nicholas John van As - The Royal Marsden NHS Foundation Trust, London, UK
Stereotactic body radiotherapy compared with surgery for localised prostate cancer ( Dr Nicholas John van As - The Royal Marsden NHS Foundation Trust, London, UK )
16 Feb 2023

Changes in planned disease management after PET/CT in men with biochemically recurrent prostate cancer and low PSA levels

Dr Frédéric Pouliot - Université Laval, Quebec, Canada
Changes in planned disease management after PET/CT in men with biochemically recurrent prostate cancer and low PSA levels ( Dr Frédéric Pouliot - Université Laval, Quebec, Canada )
16 Feb 2023